Academic Journals Database
Disseminating quality controlled scientific knowledge

Basal cell adenocarcinoma of the supraglottic larynx: treatment of recurrent disease with tamoxifen

Author(s): Christopher H. Bailey | Patrick J. Donovan | Glen J. Weiss

Journal: Rare Tumors
ISSN 2036-3603

Volume: 3;
Issue: 4;
Start page: e55;
Date: 2011;
Original page

Keywords: Basal cell adenocarcinoma | estrogen receptor | tamoxifen | supraglottic larynx

At the age of 83, a woman presented with an extremely rare cancer, basal cell adenocarcinoma (BCAC) of the supraglottic larynx. Pathology revealed a stage IVA tumor, pathological stage T4N0M0. She was treated with surgery and did not receive any adjuvant chemotherapy or radiation therapy. At the age of 93, during a routine examination, the patient was found to have palpable adenopathy and underwent a fine needle aspiration in June 2010. Pathology revealed similar histologic characteristics of her 2001 BCAC diagnosis, and further IHC stains revealed positive estrogen receptor staining.
Affiliate Program      Why do you need a reservation system?